Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer

Apeximmune said a Nature publication validated its novel PLA2G2D target and identified an enzyme-independent mechanism previously overlooked by the field. The company’s first-in-class anti-PLA2G2D antibody, AI-306, is progressing toward an IND filing in Q2 2027. The publication provides scientific validation, but the program remains preclinical and years from potential commercialization.